Compare HLIT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIT | NTLA |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 1996 | 2016 |
| Metric | HLIT | NTLA |
|---|---|---|
| Price | $11.78 | $12.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 23 |
| Target Price | $14.67 | ★ $20.02 |
| AVG Volume (30 Days) | 1.5M | ★ 3.1M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | $42.73 | N/A |
| Revenue Next Year | $18.36 | $62.75 |
| P/E Ratio | $233.20 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $8.47 | $7.95 |
| 52 Week High | $17.68 | $28.24 |
| Indicator | HLIT | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 51.41 |
| Support Level | $11.38 | $12.55 |
| Resistance Level | $12.48 | $13.88 |
| Average True Range (ATR) | 0.39 | 0.66 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 5.83 | 53.28 |
Harmonic Inc engaged in broadband access solutions that enable broadband operators to more efficiently and effectively deploy high-speed internet for data, voice, and video services for their customers and versatile and high-performance video delivery software, products, system solutions and services that enable its customers to efficiently create, prepare, store, playout and deliver a full range of high-quality broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smartphones. It has two segments, Broadband which provides broadband access solutions and related services, and Others; and Video business provides video processing and production and playout solutions and services, and Others.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.